Close Menu

NEW YORK – Dutch biotech startup Epify announced today that it has raised €500,000 ($547,000) in seed funding.

The firm will use the funding to develop a portfolio of biomarkers discovered by Maastricht University professor Manon van Engeland to detect colorectal cancer (CRC). Founded by Engeland, Epify anticipates offering the biomarkers for non-invasive diagnosis of CRC at the earliest stage possible to allow patients to benefit from therapeutic interventions while they are still healthy.  

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.